Vyvanse (lisdexamfetamine dimesylate) is an FDA-approved central nervous system stimulant used to treat ADHD and binge eating disorder (BED). While is not approved for weight loss, the use of Vyvanse for moderate-to-severe BED can lead to weight loss.
What Is Binge Eating Disorder?
BED is an eating disorder that was added to the Diagnostic and Statistical Manual of Mental Disorders (DSM–5) in 2013. It involves recurring episodes of binge eating without purging and accompanying feelings of remorse afterward.
Binge eating can lead to weight gain and ultimately obesity. It is defined as eating a significantly larger than normal portion of food in a short period of time and feeling that you cannot stop or control how much you are eating.
Episodes of binge eating can be characterized by behaviors that include:
Eating much more rapidly than normalContinuing to eat until uncomfortably fullEating large amounts when not physically hungryEating alone due to the embarrassment of how much you are eatingFeeling disgusted, depressed, or guilty afterward
To be diagnosed with BED, a marked level of distress regarding binge eating must be present, the binging must not be associated with purging or over-exercising to compensate, and the behavior must occur at least once a week for three months.
Vyvanse for Binge Eating Disorder
Individual or group therapy, including cognitive-behavioral therapy (CBT), interpersonal psychotherapy, and dialectical behavior therapy (DBT), are recommended for the treatment of BED. In addition, the U.S. Food & Drug Administration approved Vyvanse as the first drug to treat BED in 2010.
In preclinical trials of patients with moderate to severe BED, Vyvanse was shown to significantly reduce the frequency of binge eating days. It was also shown to be effective at aiding in the prevention of relapse.
Dosing
When starting Vyvanse, your doctor will likely begin at a lower dose and increase it gradually until you get the maximum benefit. The standard initial dose is 30mg taken every morning, increasing by 20mg per week for a maximum dose of 70mg a day.
Vyvanse is a controlled substance, which means it is more regulated than some other prescription drugs. In most states, you will need to see your doctor each month to obtain a new prescription. Refill requests likely cannot be made over the phone.
Precautions and Side Effects
Since Vyvanse is a central nervous system stimulant, it comes with some risks. It is in a class of drugs known as amphetamines, which have a high potential for abuse and dependence. They are also linked to serious cardiovascular reactions, including sudden death, stroke, and heart attack. People with a known hypersensitivity to amphetamine products or those who take monoamine oxidase inhibitors (MAOIs) should not take Vyvanse.
Common side effects from Vyvanse use include:
Dry mouthInsomniaDecreased appetiteIncreased heart rateConstipation Feeling jitteryAnxiety
A Word From Verywell
If you think you may have binge eating disorder, the first step to treatment should be seeking the help of a medical or behavioral health specialist. Once diagnosed, your health care provider can tell you if Vyvanse can aid in weight loss by managing your binge eating episodes.
Verywell Mind uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
Ghaderi A, Odeberg J, Gustafsson S, et al. Psychological, pharmacological, and combined treatments for binge eating disorder: a systematic review and meta-analysis. PeerJ. 2018;6:e5113. doi:10.7717/peerj.5113
Burrows T, Skinner J, Mckenna R, Rollo M. Food Addiction, Binge Eating Disorder, and Obesity: Is There a Relationship?. Behav Sci (Basel). 2017;7(3) doi:10.3390/bs7030054
Brownley KA, Berkman ND, Peat CM, et al. Binge-Eating Disorder in Adults: A Systematic Review and Meta-analysis. Ann Intern Med. 2016;165(6):409-20. doi:10.7326/M15-2455
Guerdjikova AI, Mori N, Casuto LS, Mcelroy SL. Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine. Neuropsychiatr Dis Treat. 2016;12:833-41. doi:10.2147/NDT.S80881
De jong M, Schoorl M, Hoek HW. Enhanced cognitive behavioural therapy for patients with eating disorders: a systematic review. Curr Opin Psychiatry. 2018;31(6):436-444. doi:10.1097/YCO.0000000000000452
Mcelroy SL, Hudson J, Ferreira-cornwell MC, Radewonuk J, Whitaker T, Gasior M. Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials. Neuropsychopharmacology. 2016;41(5):1251-60. doi:10.1038/npp.2015.275
Hudson JI, Mcelroy SL, Ferreira-cornwell MC, Radewonuk J, Gasior M. Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2017;74(9):903-910. doi:10.1001/jamapsychiatry.2017.1889
Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present–a pharmacological and clinical perspective. J Psychopharmacol (Oxford). 2013;27(6):479-96. doi:10.1177/0269881113482532
Coghill DR, Caballero B, Sorooshian S, Civil R. A systematic review of the safety of lisdexamfetamine dimesylate. CNS Drugs. 2014;28(6):497-511. doi: 10.1007/s40263-014-0166-2
Additional Reading
Highlights of prescribing information: Vyvance. U.S. Food and Drug Administration.
Binge eating disorder. National Eating Disorders Association.
Heo Y, Duggan S. Lisdexamfetamine: A review in binge eating disorder. CNS Drugs. 2017;31(11):1015-1022. doi:10.1007/s40263-017-0477-1
:max_bytes(150000):strip_icc()/Malia-Frey_1000-2f7768d8777a4ebbac39d628bc31b714.jpg)
Thanks for your feedback!
What is your feedback?
Helpful
Report an Error
Other
